about
Function and regulation of tau conformations in the development and treatment of traumatic brain injury and neurodegenerationEnantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography.A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an exampleDisease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexilineCSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.Novel serology testing for sporadic inclusion body myositis: disease-specificity and diagnostic utility.Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury.Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum.CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders.Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae.Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls.Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged.Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol.Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography.Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways.Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cellsLimited expression of heparan sulphate proteoglycans associated with Aβ deposits in the APPswe/PS1dE9 mouse model for Alzheimer's diseaseEffect of CYP2D6 metabolizer status on the disposition of the (+) and (???) enantiomers of perhexiline in patients with myocardial ischaemiaDiagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysisCorrection to: Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways
P50
Q28080073-BF2689C5-3561-4D9B-BE9B-0E7C12BF661FQ31030469-3B02C900-CC51-4443-AD02-48E326A2AEB6Q36323907-A3216E5B-ACC6-4472-8628-DF0C136581A9Q36424500-46083A09-B662-4074-A05E-AB14C64D03F3Q36535908-38C7B612-4A83-4C24-80CF-24D7CD09AF01Q38145962-60AB47EE-3402-4387-BEC7-B81AFD8959FAQ38569024-3D084653-CA2C-4130-A1D2-CB9EF31916C5Q38960994-B00160E9-5A90-43B6-AC66-080F2DBC1876Q38999120-384D1D08-8584-46EE-A8E6-6779061F274EQ39021882-57AD5DFA-50C6-4813-86A2-A5CA5AEDE2FDQ40267156-D8B4743F-44C6-4AC6-BBFF-A514FBB2FBC6Q42379648-D565FF90-9004-4C09-BD9F-0F816CAF47ABQ43517732-A13C8218-6CF1-4DE8-814F-C887B26EA690Q48380481-4D9F456A-4B74-4C94-8BD7-C6F512B9B399Q48542914-46704A75-3839-47C8-8E37-AE5B57CF72E4Q48869931-5A74F5BF-AFAD-40F6-BB62-FC433D52945CQ53006904-4A47E2D9-D100-4672-9DCE-7D71D58502DCQ54917620-F492481E-D932-4E1C-8DFA-5C9B5B1CF170Q58793896-AFE78F70-A69E-4A68-910E-176F8927C266Q61311901-4A72555E-9044-43C5-9C15-B04284DE4425Q61311927-198FDD3A-E9EB-4FA5-8EAC-F90E001DD81EQ64761571-6FCCE471-22CF-4248-AE47-BBB2F4817345Q89572851-97F2EFF3-15B6-4CDA-94CA-6E6F18CDD4EC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Megan K Herbert
@ast
Megan K Herbert
@en
Megan K Herbert
@es
Megan K Herbert
@nl
Megan K Herbert
@sl
type
label
Megan K Herbert
@ast
Megan K Herbert
@en
Megan K Herbert
@es
Megan K Herbert
@nl
Megan K Herbert
@sl
prefLabel
Megan K Herbert
@ast
Megan K Herbert
@en
Megan K Herbert
@es
Megan K Herbert
@nl
Megan K Herbert
@sl
P1053
E-6348-2015
P106
P21
P31
P3829
P496
0000-0003-1599-4362
P569
2000-01-01T00:00:00Z